Alan Mark Mancini is a notable inventor based in Indian Head Park, IL (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of modified-release metronidazole compositions. With a total of 2 patents, Mancini's work has the potential to enhance treatment options for microbial infections.

Latest Patents

Mancini's latest patents focus on pharmaceutical compositions that provide a modified release profile for once-daily dosing of metronidazole. These compositions are designed to exhibit substantial bioequivalence to immediate-release metronidazole administered three times per day. The innovative formulations include a specific percentage of metronidazole, along with various excipients that enhance the drug's release characteristics and overall effectiveness.

Career Highlights

Throughout his career, Mancini has been associated with G.D. Searle & Company, where he has contributed to the advancement of pharmaceutical technologies. His work has been instrumental in developing formulations that improve patient compliance and therapeutic outcomes.

Collaborations

Mancini has collaborated with esteemed colleagues such as Subhash Desai and Steven C. Schumann. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas in the pharmaceutical field.

Conclusion

Alan Mark Mancini's contributions to pharmaceutical innovations, particularly in modified-release formulations, highlight his role as a key inventor in the industry. His work continues to influence the development of effective treatments for microbial infections.